Bridge crossed by HeartWare
Tuesday, 23 September, 2008
The US FDA has approved the left ventricular assist system [LVAS] developed by HeartWare [ASX: HTW] for an Investigational Device Exemption (IDE).
The company is now clear to conduct clinical trials of the device, which are to be held at the Washington Hospital Centre, with one patient already enrolled.
The trial is a bridge-to-transplant trial in patients with end-stage heart failure.
HeartWare is in the process of finalising contractual arrangements at a number of additional centres. Seven centres so far have been trained in the use of the product.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
